Confirmed wheezing in infancy as basis for molecular fingerprinting in the prediction of asthma.

Confirmed wheezing in infancy as basis for molecular fingerprinting in the prediction of asthma. - Dutch Europrevall Asthma study: EuroPA-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33199

Enrollment

1000

Registered

2009-09-15

Start date

2009-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

None listed

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: Age between 0 and 2 years Informed consent from both parents / guardian

Exclusion criteria

Exclusion criteria: Known metabolic, genetic or syndromal disorders Known inflammatory diseases Known underlying respiratory tract disease like congenital airway abnormalities, cystic fibrosis, primary ciliary dyskinesia, brunchopulmonary dysplasia or bronchiectasis.

Design outcomes

Primary

Measure	Time frame
Primary outcome - Asthma at the age of 5 years, objectively established on basis of a validated combination of symptoms and/or the use of asthma medication, in combination with spirometry and increased bronchial hyper responsiveness, based upon the then applicable international standards.	—

Countries

Netherlands

Outcome results